Mural Oncology plc financial data

Symbol
MURA on Nasdaq
Industry
Pharmaceutical Preparations
Location
10 Earlsfort Terrace, Dublin 2, Ireland
State of incorporation
Ireland
Fiscal year end
December 31
Former names
Mural Oncology Ltd (to 8/24/2023)
Latest financial report
10-Q - Q3 2024 - Nov 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 915 %
Debt-to-equity 14.4 %
Return On Equity -70.1 % -104%
Return On Assets -61.3 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 17.1M shares
Common Stock, Shares, Outstanding 17M shares
Entity Public Float 81.4M USD
Common Stock, Value, Issued 170K USD
Weighted Average Number of Shares Outstanding, Basic 17M shares +2.03%
Weighted Average Number of Shares Outstanding, Diluted 17M shares +2.03%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 124M USD -31.6%
General and Administrative Expense 36.7M USD +9.3%
Operating Income (Loss) -161M USD +26.4%
Income Tax Expense (Benefit) 1.98M USD -100%
Net Income (Loss) Attributable to Parent -154M USD +21.7%
Earnings Per Share, Basic -9.14 USD/shares +39.1%
Earnings Per Share, Diluted -9.14 USD/shares +39.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 111M USD
Other Assets, Current 751K USD -72.2%
Assets, Current 184M USD +3605%
Property, Plant and Equipment, Net 8.85M USD -18.9%
Operating Lease, Right-of-Use Asset 8.63M USD -39%
Other Assets, Noncurrent 27K USD -85.1%
Assets 203M USD +573%
Accounts Payable, Current 2.24M USD -36%
Employee-related Liabilities, Current 5.43M USD -4.44%
Accrued Liabilities, Current 17.2M USD +1.86%
Liabilities, Current 24.9M USD -5.66%
Operating Lease, Liability, Noncurrent 4.1M USD -60.8%
Other Liabilities, Noncurrent 115K USD -47.5%
Liabilities 29.1M USD -21.5%
Retained Earnings (Accumulated Deficit) -125M USD
Stockholders' Equity Attributable to Parent 174M USD
Liabilities and Equity 203M USD +573%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -37.3M USD +33%
Net Cash Provided by (Used in) Investing Activities -125M USD -31191%
Common Stock, Shares Authorized 450M shares
Common Stock, Shares, Issued 17M shares
Common Stock, Par or Stated Value Per Share 0.01 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -162M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 113M USD
Deferred Tax Assets, Valuation Allowance 5.93M USD -95%
Operating Lease, Liability 9.55M USD -42.1%
Depreciation 3.18M USD +12.5%
Payments to Acquire Property, Plant, and Equipment 55K USD -86.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -31.7M USD +38.3%
Lessee, Operating Lease, Liability, to be Paid 9.87M USD -42.7%
Property, Plant and Equipment, Gross 45.2M USD +2.18%
Operating Lease, Liability, Current 5.44M USD -9.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.48M USD -62.6%
Lessee, Operating Lease, Liability, to be Paid, Year One 6.64M USD +2.25%
Operating Lease, Weighted Average Discount Rate, Percent 0.04 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 319K USD -57%
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.48M USD
Deferred Tax Assets, Operating Loss Carryforwards 714K USD -99%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 50M shares
Unrecognized Tax Benefits 0 USD -100%
Additional Paid in Capital 299M USD
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 3.32M USD -32.1%
Share-based Payment Arrangement, Expense 19.7M USD -65.5%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares